Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Adial Pharmaceuticals (ADIL) EBITDA (2022 - 2024)

Adial Pharmaceuticals' EBITDA history spans 3 years, with the latest figure at -$1.9 million for Q4 2024.

  • For Q4 2024, EBITDA fell 116.93% year-over-year to -$1.9 million; the TTM value through Dec 2024 reached -$6.6 million, down 10.5%, while the annual FY2025 figure was -$7.8 million, 5.85% up from the prior year.
  • EBITDA for Q4 2024 was -$1.9 million at Adial Pharmaceuticals, up from -$2.2 million in the prior quarter.
  • Across five years, EBITDA topped out at -$631537.0 in Q2 2024 and bottomed at -$3.2 million in Q2 2022.
  • The 3-year median for EBITDA is -$2.1 million (2024), against an average of -$2.1 million.
  • The largest annual shift saw EBITDA surged 65.56% in 2023 before it tumbled 116.93% in 2024.
  • A 3-year view of EBITDA shows it stood at -$2.6 million in 2022, then soared by 65.56% to -$894649.0 in 2023, then crashed by 116.93% to -$1.9 million in 2024.
  • Per Business Quant, the three most recent readings for ADIL's EBITDA are -$1.9 million (Q4 2024), -$2.2 million (Q3 2024), and -$631537.0 (Q2 2024).